Comments on "Electric current and electric field induced in a human body when exposed to an incident electric field near the resonant frequency" [with reply]
For original paper see ibid., vol. 48, no. 9, p. 147-53 (2000). The author makes two observations on the original article. The commentator questions whether a seated person is well modeled as a right circular cylinder. The second observation is that King cites only microwave studies on mice to show that electromagnetic radiation causes malignancies. These studies themselves are widely disputed. He then uses simple dimensional scaling to show that 2.45 GHz for a mouse scales to 100 MHz for a man. Such a scaling law may be useful in calculating the resonant frequency for a human subject versus a mouse when treated as antennas, but such scaling is meaningless when the physics of a hypothetical carcinogenic process are unknown.
Electric current and electric field induced in the human body when exposed to an incident electric field near the resonant frequency
The electric field and current density induced in the human body when this is exposed to electric fields near the resonant frequency, 53 MHz, are determined analytically. Since this frequency range includes an important amateur radio band of 50-60 MHz and exposure to electric fields at this frequency has been shown to be hazardous, the study has a specific motivation. A cylindrical model of the body is used to derive formulas for the total axial current and current density induced in the body subject to skin effect. Tabulations and graphical representations illuminate the results.
Antitumor activities of (2"R)-4'-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors.
(2''R)-4'-O-Tetrahydropyranyladriamycin (THP) is a new derivative of doxorubicin (adriamycin, ADM). The concentrations of THP and ADM required to inhibit by 50% the growth of a cultured L1210 cells was 0.003 microgram/ml and 0.016 microgram/ml, respectively. Various therapeutic designs of combinations of THP with other antitumor agents were investigated in vivo using the L1210 murine leukemia. The combination of THP with cytosine arabinoside (Ara-C), cyclocytidine hydrochloride (Cyclo-C), 6-mercaptopurine (6-MP) and cyclophosphamide (EX) showed a great effectiveness following daily intraperitoneal treatment from days 1 to 10. High therapeutic effects were also obtained with the combinations of THP with Ara-C, Cyclo-C, vincristine (VCR) and EX following intravenous combination therapy one day following implantation of L1210 leukemia. Schedule dependency and its therapeutic efficacy of THP were examined. THP showed almost the same antitumor activity on the solid-type sarcoma-180 or solid-type Ehrlich carcinoma as ADM by intraperitoneal or intravenous treatment. THP showed some superior activity to ADM in the advanced stage of L1210 leukemia. High antitumor activity of THP on murine leukemia L1210 has been reported by Tsuruo et al. (Cancer Res. 42: 1462-1467, 1982) and was also confirmed. THP gave many mice cures, especially in the intravenous treatment.